1. Introduction {#sec1-pharmaceutics-12-00203}
===============

Nowadays, people (0.50--1.0%) are suffering from serious neurological disorders, one example of which is epilepsy \[[@B1-pharmaceutics-12-00203],[@B2-pharmaceutics-12-00203],[@B3-pharmaceutics-12-00203]\]. Numerous treatment processes are applied (surgery, drugs, and yoga) in order to control convulsions. Medicine is still one the most important parts of the treatment for seizures \[[@B4-pharmaceutics-12-00203]\]. The researchers are focusing on glutamatergic neurotransmission and GABAergic (gamma--aminobutyric acid--ergic), which is the main path of the central nervous system for excitatory and inhibitory activity \[[@B5-pharmaceutics-12-00203],[@B6-pharmaceutics-12-00203]\]. NHEs (sodium--hydrogen exchangers) are also involved in the regulation of seizures' activity for the neuronal cells \[[@B7-pharmaceutics-12-00203],[@B8-pharmaceutics-12-00203]\].

Medicine from natural sources is one the most important treatments, in addition to its use for medicinal, culinary, dietary, and curative purposes. Traditional and alternative source of medicines from plant sources are relied on for the development of good health and fewer side effects \[[@B9-pharmaceutics-12-00203]\]. *Camellia sinensis* dried plant tea leaves are one of the most famous liquid refreshment drinks worldwide, followed similarly by water, which is the second most consumed \[[@B10-pharmaceutics-12-00203]\]. Consumers use the leaves in the form of black tea, oolong tea, or green tea. Green tea in the market is attracting many people around the world, owing to various epidemiological and clinical studies data reporting positively on the prevention of many diseases. These established data have stated decreasing risk for cardiovascular diseases in terms of hypertension, myocardial infarction, and atherosclerosis; as well as for some degenerative diseases of neurons like Alzheimer's and Parkinson's diseases; followed by some specific cancers like gastric, cervical, and breast cancers, through the consumption of green tea by people \[[@B11-pharmaceutics-12-00203],[@B12-pharmaceutics-12-00203],[@B13-pharmaceutics-12-00203],[@B14-pharmaceutics-12-00203],[@B15-pharmaceutics-12-00203]\]. All these effects came about thanks to the presence of the highest quantity of catechins (i.e., polyphenolic flavonoid compounds) in the green tea \[[@B14-pharmaceutics-12-00203],[@B16-pharmaceutics-12-00203]\]. In the current time, there has been increased curiosity about the use of herbal drugs as another option for the development of formulations in therapeutic uses of various neurodegenerative diseases like epilepsy. All the mentioned effects of catechins are accredited to their antioxidant and anti-inflammatory action. Catechins are phytochemicals, richly present in black grapes, peaches, strawberries, and broad beans. Catechins occurring in various forms, such as epicatechin, catechins, catechin hydrate, epigallocatechin, epicatechin gallate, and epigallocatechin gallate, were reported to be used in the treatment of epilepsy \[[@B17-pharmaceutics-12-00203],[@B18-pharmaceutics-12-00203]\]. Green tea and grape seed contained a sufficient amount of flavonoid that is, catechin hydrate (CH) \[[@B19-pharmaceutics-12-00203]\]. It has also been proven previously that CH showed antioxidant and anti-inflammatory activities \[[@B20-pharmaceutics-12-00203]\]. In the presence of these situations, the current study was designed to develop a novel nanoformulation and to evaluate the anticonvulsive effect of CH against epileptic induced rats.

Many researchers are focusing on nose-to-brain drug delivery systems as they have many advantages such as hepatic first pass metabolism, avoiding the blood brain barrier (BBB), and being a non-invasive route with easy administration of drugs \[[@B21-pharmaceutics-12-00203],[@B22-pharmaceutics-12-00203],[@B23-pharmaceutics-12-00203]\]. Before designing the intranasal preparations, it is important to understand the problem of the short-stay time of the drug in the nasal cavity. It is highly recommended to develop formulations that contain maximum viscosity with mucoadhesive property; this will increase the nasal residence time. We can design the mucoadhesive formulation administered intranasally to enhance the absorption of the CH drug. We can design a certain dosage form that is helpful for increasing the nasal mucoadhesive time. Nowadays, in situ nasal gel formulations are an attractive tool used as biocompatible and biodegradable nanoparticles (NPs) for the sustained and controlled release of catechin hydrate (CH) \[[@B24-pharmaceutics-12-00203],[@B25-pharmaceutics-12-00203],[@B26-pharmaceutics-12-00203],[@B27-pharmaceutics-12-00203],[@B28-pharmaceutics-12-00203]\]. Polymeric NPs are attaining a great attention because of their ability to lengthen the therapeutic action, control the drug release rate, contain the maximum loading drug capacity (DL), and enhance the surface area. In this way, the drug will release rapidly when compared with various types of carriers and drug delivery systems for the specific sites targeted to the body. Polymeric NPs also provide additional advantages as compared with other nose-to-brain drug delivery systems because these NPs protect the drugs that are encapsulated, avoiding the direct involvement of biological degradation by chemical and extracellular transport via efflux of p-glyco proteins. Finally, it enhanced the bioavailability of drugs into the brain. NPs had a very small diameter, which is very useful for the transcellular transportation through olfactory neurons into the brain via various endocytic pathways of neuronal cells for the treatment of Parkinson's disease via olfactory membranes \[[@B26-pharmaceutics-12-00203],[@B27-pharmaceutics-12-00203],[@B28-pharmaceutics-12-00203]\]. Therefore, these nanoparticles can be a better approach in the comparison of in situ nasal gel. Poly(lactic-*co*-glycolic acid) nanoparticles, that is, PLGA--NPs, having an optimum size, shape, and a specific surface, have been linked with the ligand, which is mostly utilized for intranasal brain targeting of the drugs \[[@B29-pharmaceutics-12-00203]\]. PLGA--NPs are known to be biodegradable, biocompatible, and non-toxic, and have been used in biomedical applications for more than two decades. PLGA has been widely investigated for the formulation of NPs because of its biocompatibility, safety, ability to promote mucoadhesion, and enhanced drug stability via intranasal drug delivery as compared with other routes of drug administration \[[@B30-pharmaceutics-12-00203],[@B31-pharmaceutics-12-00203]\]. PVA--NPs (polyvinyl alcohol NPs) are also used similarly because of the maximum permeability, better solubility, and increased compatibility of mixtures with excellent rheological properties on the various shapes and flexibility through many types of drug delivery \[[@B32-pharmaceutics-12-00203]\]. Nowadays, chitosan exhibited a mucoadhesive nature, which attracted great attention in different fields like protein and metal adsorption \[[@B27-pharmaceutics-12-00203],[@B28-pharmaceutics-12-00203],[@B33-pharmaceutics-12-00203]\]. Coating on the NPs' surface by chitosan (CS) has been shown to be useful in many applications like a sustained release of drug delivery, with mucoadhesive properties resulting in the enhancement of the drug absorption and prolonged release of drugs \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203],[@B35-pharmaceutics-12-00203]\], decreasing the burst release of drugs because of the surface modification, and also enhancing the permeation and retention of NPs. This mechanism occurs because of the interest taken between the positively-charged CS and negatively-charged membrane \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203],[@B35-pharmaceutics-12-00203]\].

Likewise, the literature survey \[[@B33-pharmaceutics-12-00203],[@B36-pharmaceutics-12-00203],[@B37-pharmaceutics-12-00203],[@B38-pharmaceutics-12-00203],[@B39-pharmaceutics-12-00203],[@B40-pharmaceutics-12-00203],[@B41-pharmaceutics-12-00203],[@B42-pharmaceutics-12-00203],[@B43-pharmaceutics-12-00203]\] reports different methods for sample analysis of fruit juices, green tea or tea extracts, and coffee or other plant extracts. Although, most of these research studies reported simultaneous development with other catechins at the same time, that is, no reports of plasma analysis are available for catechin individually. Only one method was reported in urine sample analysis for catechins by Lendoiro et al. \[[@B44-pharmaceutics-12-00203]\]. In addition, the most important reason for the proposed study is a lack of an available method for brain tissue as well as plasma analysis of catechin hydrate alone. Likewise, no report is available for the quantification of CH up to picogram level in either the plasma or brain tissue. In this research study, we developed a new bioanalytical method of catechin hydrate and validated it successfully for the evaluation of the pharmacokinetic (PK) parameters of CS-coated--PLGA--NPs by ultra high performance liquid chromatography (UHPLC)-electrospray ionization (ESI)-triple-quadrupole-mass spectroscopy and mass spectroscopy (MS/MS). This developed bioanalytical method exhibited many applications in terms of higher efficiency, maximum sensitivity, minimum retention, and run time for the evaluation of PK parameters in plasma as well as brain in a shorter time. Additionally, the developed method is also recommended for the quantification of CH in the lungs for PK study.

The proposed research is a first time study designed to develop a new nanoformulation of chitosan (CS)-coated--PLGA--NPs for enhanced brain targeting of CH. The main aim is to enhance CH bioavailability in the brain after the intranasal delivery of CH nanoformulations, to attain a high drug therapeutic level in the central nervous system (CNS), while avoiding the unwanted systemic exposure of the drug, along with the dose requirement for therapeutic advantage of the brain or systemic. CS-coated--PLGA--NPs exhibited the best effective solubility and permeability. CS-coated--CH-loaded--PLGA--NPs were developed and characterized for many physicochemical characteristics to evaluate their appropriateness for nose-to-brain drug delivery. A comparative research study was evaluated for the CH--S, CH-loaded--PLGA--NPs, and CS-coated--CH-loaded--PLGA--NPs in the brain, along with evaluation of PK parameters (C~max~, t~1/2~, area under curve (AUC)~0--t~, K~el~, and so on) with their comparative bioavailability and study by the successfully developed and validated UHPLC-MS/MS method in the treatment of epilepsy (increasing current electroshock (ICES) and pentylenetetrazole (PTZ)) induced seizures for both rodent models.

2. Materials and Methods {#sec2-pharmaceutics-12-00203}
========================

Catechin hydrate (purity 99.98%) was purchased from AK Scientific, Inc. 30023 Ahern Avenue Union City, CA 94587, USA. Chitosan from Tokyo Chemical Industry Co., Ltd. 6-15-9 Toshima, Kita-ku, Tokyo 114-0003, Japan. Poly (vinyl alcohol, MW 25,000) and PLGA were purchased from Polysciences Inc, 400 Valley Road and dichloromethane (DCM) was purchased from Sigma Aldrich Corporation (St. Louis, MO, USA). HPLC-grade methanol, acetonitrile, ammonium formate, ammonium acetate, and formic acid were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). Milli\--Q\--Water was used in the whole analysis. All the other chemicals used that were of analytical grade were obtained from different commercial sources.

2.1. Preparation of Nanoparticles {#sec2dot1-pharmaceutics-12-00203}
---------------------------------

CH--PLGA--NPs were prepared and optimized through a previously used method, that is, double emulsion methods with slight modification \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\]. In a summarized form, CH (10.00 mg) was dissolved in PVA solution (400 µL, 1.1% *w*/*v*, pH 3.0 adjusted) and PLGA (50.00 mg) was dissolved in dichloromethane (DCM; 8.0 mL). Emulsification of polymeric solution was sonicated (over an ice bath) in drug solution for 1.5 min (duty cycles (40%), 25 W, Sonopuls, Bandelin, Germany). Previously prepared w/o primary emulsion was added drop by drop up to 8.0 mL of aqueous phase (external, 1.0% *w/v* PVA) under sonication (25% amplitude, over an ice bath, 2.0 min). Finally, the resultant dispersion preparation, that is, secondary emulsion (w/o/w), was exposed under gentle magnetic stirring (400.00 rpm) for evaporation of the solvent at room temperature. Following evaporation of the solvent, the resultant nano-suspension was centrifuged (with 18,000 rpm for 20.0 min), and the pellets were washed and lyophilized for 24.0 h (−50 °C, 0.015 mbar pressure) to attain free flowing and simply dispersible lyophilized nanoparticles (Lab Conco., LPYH, Lock 6, USA freeze dryer).

2.2. Optimization by Central Composite Design {#sec2dot2-pharmaceutics-12-00203}
---------------------------------------------

A four-factor, three-level central composite experimental design (CCD) \[[@B21-pharmaceutics-12-00203]\] was employed for the optimization and evaluation of the correlation between the independent variables like PLGA (X~1~), PVA (X~2~), sonication time (X~3~), and temperature (X~4~), and the dependent (responses) variables including particle size (Y~1~), polydispersity index (PDI) (Y~2~), and zeta potential (Y~3~) ([Table 1](#pharmaceutics-12-00203-t001){ref-type="table"}). On the other side for the prediction of better response, CCD is better as compared with the Box--Benhnken design (BBD) \[[@B21-pharmaceutics-12-00203]\], as BBD suggested formulation only, that is, independent variables' values (lower, middle, and higher). CCD, however, included two additional values, (+α) and (--α), in addition to the above-mentioned values in which the rotatability necessities of the design are enclosed \[[@B21-pharmaceutics-12-00203]\]. As per the experimental runs, the preparation of a total of 30 formulations was constructed ([Table 2](#pharmaceutics-12-00203-t002){ref-type="table"}). CCD was suggested to run a total of 30 randomized formulations on the basis of given values. On the basis of the total of 30 formulation runs, 16 were treated as the main suggested formulation with eight-axial points, followed by six as the centre points. In the end, the required constraints were applied. CCD software (Design-Expert 12, Stat-Ease, Inc., 1300 Godward St NE, Suite 6400, Minneapolis, MN 55413-2561, USA) based on the four-factor, three-level was suggested as a quadratic polynomial equation, given below:

2.3. Nanoparticles' Characterizations {#sec2dot3-pharmaceutics-12-00203}
-------------------------------------

### 2.3.1. Particle Size, PDI (Polydispersity Index), and Zeta Potential {#sec2dot3dot1-pharmaceutics-12-00203}

Measurement of the particle size is the most important parameter. The lower the particle size, the greater the surface area for the absorption of drug \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\]. The particle size, polydispersity index, and Zeta potential of optimized NPs were measured by dynamic light scattering (Malvern--Zetasizer, Nano--Zetasizer, Worcestershire, UK. The nano-formulations were diluted prior to size analysis. The temperature maintained for the particle size analysis, that is, 25 °C, and the scattering angle were also fixed (90°) \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\]. The diluted sample of the nano-formulations was used to analyse the size and surface charge, where each measurement was made in triplicate.

### 2.3.2. Chitosan Coating on Optimized CH--PLGA--NPs {#sec2dot3dot2-pharmaceutics-12-00203}

For chitosan-coated--PLGA--NPs' preparation, a specific-volume of CH--PLGA--NPs was kept at room temperature for 2.0 h with an equivalent volume of CH, that is, 2.0 mg/mL or 4.0 mg/mL chitosan in the 0.50% of acetic acid \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\]. The CS (2%)-coated--PLGA--NPs and CS (4%)-coated--PLGA--NPs were produced, centrifuged, washed twice, and then redispersed in the same volume of distilled water. Finally, they were dried with the help of a lyophilizer at −60.0 °C for four days (Labconco, TriadTM, USA) for the stability of NPs. These formulations were prepared in triplicate.

### 2.3.3. Scanning Electron Microscopy (SEM) {#sec2dot3dot3-pharmaceutics-12-00203}

The shape of particles was determined by scanning electron microscopy (SEM) (FEI, INSPECT S50, Czech Republic). The proposed method was adopted from Ahmad et al. \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203]\].

### 2.3.4. Transmission Electron Microscopy (TEM) {#sec2dot3dot4-pharmaceutics-12-00203}

The globule size of optimized nanoparticles was examined by transmission electron microscopy (TEM) (FEI, MORGAGNE.68, Czech Republic). The proposed method was adopted by Ahmad et al. \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203]\].

### 2.3.5. Loading Capacity (%LC), Entrapment Efficiency (%EE), and %Process Yield of Prepared and Optimized Nanoparticles {#sec2dot3dot5-pharmaceutics-12-00203}

The EE (entrapment efficiency) and LC (loading capacity) of NPs was determined by ultracentrifugation (at 15,000 rpm; 30 min at 4 °C). In-house reported in this manuscript, the UHPLC--MS/MS method was used to evaluate and validate the free quantity of CH in supernatant \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203]\]. After triplicate measurements, the following equation was used to calculate LC and EE for developed and optimized nanoparticles \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203]\]:$$EE~\left( \% \right) = \frac{Total~Quantity~of~CH - Free~Quantity~of~CH}{Total~Quantity~of~CH}$$ $$LC~\left( \% \right) = \frac{Total~Quantity~of~CH - Free~Quantity~of~CH}{Weight~of~Nanoparticles}$$

Process yield (%) was calculated using the proposed formula:$$Process~Yield~\left( \% \right) = \frac{W_{1}~\left( {Weight~of~Dried~Nanoparticles} \right)}{W_{2}~(Total~Dried~Weight~of~Starting~Materials)}$$

### 2.3.6. DSC (Differential Scanning Calorimetry) Study {#sec2dot3dot6-pharmaceutics-12-00203}

DSC 214 Polyma (NETZSCH---Wittelsbacherstraße 42, 95100 Selb, Germany) was used to determine the DSC of pure catechin (CH); polymer (PLGA); poly vinyl alcohol (PVA); a physical mixture of CH, PVA, and PLGA; freeze-dried--CH-loaded-optimized polymer (PLGA)--NPs; pure chitosan; and CS-coated--CH-loaded--optimized polymer (PLGA)--NPs. The sample (10 mg) was kept inside a standard aluminium pan, crimped, and heated (20.0 °C to 400.0 °C) at a rate of 10.0 °K/min, followed by a continuous supply of nitrogen \[[@B21-pharmaceutics-12-00203],[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203]\].

### 2.3.7. Fourier Transform Infrared Spectroscopy (FTIR)-Based Attenuated Total Reflection (ATR) {#sec2dot3dot7-pharmaceutics-12-00203}

Functional groups and chemical structures with their composition of the compounds were evaluated by FTIR-based ATR (NICOLET iS50 FT-IR; Thermo Fisher Scientific, 5225 Verona Road, Madison, WI 53711, USA). IR spectra of pure catechin hydrate (CH), PVA, PLGA--NPs, CH-loaded--PLGA--NPs, chitosan, and chitosan-coated--CH-loaded--PLGA--NPs were examined through an attenuated total reflectance (ATR, wavenumber 4000--400 cm^−1^). All the samples were analysed in their original forms without any kind of preparation \[[@B46-pharmaceutics-12-00203]\].

2.4. In Vitro Drug Release {#sec2dot4-pharmaceutics-12-00203}
--------------------------

In vitro release of CH from catechin hydrate suspension (CH--S) and optimized (opt)-both-NPs was carried out from the dialysis membrane (treated before) (pore size: 2.40 nm, molecular weight cut-off ∼12--14 kD) \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\]. First, the release medium was prepared (phosphate buffer/ethanol of 7:3; pH 7.4 = 100 mL). The temperature was maintained at 37 ± 1 °C with the help of a stirrer up to 6 h at 100 rpm. Finally, the dialysis bag was properly checked for any leak and CH--NPs (containing 0.50 mg CH) were placed inside. For the CH release study from the NPs selected, the selected time points were predetermined (i.e., 30, 60, 120, 240, 360, 480, 720, and 1440 min). At every time point, we withdrew the test samples (1.0 mL). All samples were withdrawn and filtered by syringe filter (0.2 μm), after which the CH quantity was analysed through the in-house developed and validated UHPLC--MS/MS method reported in this manuscript \[[@B28-pharmaceutics-12-00203],[@B46-pharmaceutics-12-00203]\].

2.5. Nasal Mucosa Based Ex Vivo Permeation Studies {#sec2dot5-pharmaceutics-12-00203}
--------------------------------------------------

Nasal tissues were taken out freshly and carefully from the goat's nasal cavities provided by the local slaughterhouse. Tissue cells (a fix area) were decided to be used to permeate the drug (0.785 cm^2^; Logan Instrument Corporation, Piscataway, NJ, USA). Phosphate buffer saline (20 mL PBS; pH 7.4, at 37 °C) was added to the receptor chamber, while pure CH suspension, freeze-dried CH-loaded-optimized--PLGA--NPs, and freeze-dried CS-coated--CH-loaded--optimized--PLGA--NPs (\~10.0 mg of CH) were kept in the donor chamber (21.5 to 2 mL) after the preincubation time (20 min in each case). Then, 0.500 mL samples (on predetermined time intervals) were withdrawn from the receptor chamber. The samples were filtered via a membrane filter for the analysis. The quantity of permeated CH was analysed through the in-house developed and validated UHPLC--MS/MS method reported in this manuscript \[[@B46-pharmaceutics-12-00203]\].

2.6. In Vivo Study {#sec2dot6-pharmaceutics-12-00203}
------------------

Ethical Committee of Imam Abdulrahman Bin Faisal University (IAU) gave us ethical approval to perform the pharmacokinetics and pharmacodynamics studies (Approval Number: IRB-UGS-2019-05-312, date of approval: 7 November 2019). Albino rats (weight; 180--200 g) were grouped (5 to 10 in each cage) and maintained in natural light followed by a dark cycle with freely reachable food and water (temperature: 20.0 to 30.0 °C, humidity: 50.0% to 55.0%). Albino rats of 180 to 200 g in weight were taken and kept in the cages on the basis of their predetermined groups. We also maintained a natural light/dark cycle with freely reachable food and water (temperature: 20--30 °C, humidity: 50--55%). All of the rats were kept under all of the prescribed conditions of the laboratory. At the wake up time, that is, the light cycle, the research work was started with freely moving rats.

2.7. Development and Validation of Bioanalytical Method {#sec2dot7-pharmaceutics-12-00203}
-------------------------------------------------------

At the time of the development of bioanalytical methods and their validation for catechin hydrate of plasma, lungs, and brain homogenate, the U.S. FDA 2001 guidelines were followed. Eight levels of non-zero concentration for the calibration curve (CC) were selected to plot linearity and calculate the peak area ratio; 1/*x*^2^ weighed linear smallest square regression was used. The noise ratio (10:1) was used as a signal to determine the LLOQ (lower limit of quantification) of the CC (LLOQ), in which HQC (higher quality control), medium QC (MQC), and lower QC (LQC) were used to examine the efficiency of CH extraction. For the evaluation of plasma, lungs, and brain homogenate samples, we took six pre-spiked extracted samples (mean area response) versus post-extraction spiked CH-free in the matrix. Similarly, the recovery of internal standard (IS) samples was also estimated. For the estimation of inter- and intra-day precision and accuracy, we analysed six replicates of LLOQ of quality control (LLOQQC), LQC, MQC, and HQC with a CC of plasma, lungs, and brain homogenate samples.

2.8. UHPLC--MS/MS Conditions {#sec2dot8-pharmaceutics-12-00203}
----------------------------

UHPLC--MS/MS, that is, Pinnacle DB C18 (1.9 µm; 50 × 30.0 mm), using a binary solvent manager autosampler with a very sensitive and high resolution tunable mass detector (LCMS-8050, ESI, Triple Quadrupole, Kyoto, Japan), was employed. Chromatographic conditions were used as Pinnacle DB C18 (1.9 µm; 50 × 30.0 mm), mobile phase (methanol/formic acid (0.01%): 54:36), flow rate (0.250 mL min^−1^), and 5.0 µL injection volume with a total run time of 2.0 min. For mass determination, a very sensitive and high resolution tunable mass detector (LCMS-8050, ESI, Triple Quadrupole, Kyoto, Japan) was applied through operating conditions as follows: argon as collision gas, 1.0 min scan time, inter-scan delay (0.02 s with 0.1 µ scan step: 30,000 µ/s), where for quantification of CH and IS, the parameters were used as collision energy (17.0 eV CE; for CH and 21.0 eV for quercetin) with --ve ion mode. The parameters for bioanalysis illustrated a transition at m/z 289.20/245.20 and 301.21/151.21 for CH and quercetin (IS), respectively ([Figure 1](#pharmaceutics-12-00203-f001){ref-type="fig"} and [Figure 2](#pharmaceutics-12-00203-f002){ref-type="fig"}). For the accurate mass calculation with the concentration of analyte, as well as evaluation of precursor and fragment ions, we used the Lab Solution Software Version 5.93 (Kyoto, Japan).

2.9. Preparation of QC and CC Samples {#sec2dot9-pharmaceutics-12-00203}
-------------------------------------

First, we prepared standard CH stock solution in the methanol, that is, 1 mg mL^−1^ and then other dilutions for eight different concentrations of CC with the help of 2% analyte (aqueous) in blank matrix (plasma, lungs, and brain homogenate) of the rats, that is, analyte (20.0 mL of aqueous) + 980.0 mL matrix (blank). We prepared the CC samples at a range (1.00--1000.00 ng/mL) for CH with eight different time points (1.0, 2.0, 22.0, 210.0, 420.0, 640.0, 850.0, and 1000.0 ng/mL) in the different matrixes. Similarly, we also prepared the QC samples HQC (800.00), MQC (410.00), LQC (2.90), and LLOQC (1.01) with IS (50.00 ng ml^−1^) in a mixture of water/methanol (1:1). All the spiking dilutions prepared freshly and stored at a temperature of 2.0--8.0 °C.

2.10. Extraction of Different Matrix Samples {#sec2dot10-pharmaceutics-12-00203}
--------------------------------------------

Fresh known samples (CC and QC) with unknown samples of lungs, brain homogenate, or plasma were prepared and collected for analysis. For the extraction of all the matrix samples, 750.0 μL of each aliquot was taken in a fresh-cleaned glass tube and then added to 50.0 ng mL^−1^ of 100.0 μL of IS. Then, 250 μL 5.0% formic acid was added by 300 rpm vortexing up to 6.0 min for the breaking of matrixes' protein. All these samples were centrifuged at 4000 rpm for 10.0 min at 4.0 °C, and then transferred to 4.0 mL supernatant sample in a clean glass tube. Transferred samples were evaporated at 37.0 °C in a water bath for the purpose of drying the samples under nitrogen stream. Finally, the residues were reconstituted from a 650.0 μL mobile phase with the help of 300 rpm vortexed for 5.0 min. All the reconstituted samples were transferred to UHPLC vials for bioanalysis.

2.11. Pharmacokinetic (PK) Study {#sec2dot11-pharmaceutics-12-00203}
--------------------------------

We selected six groups for PK study, **Group 1:** CH--S (i.n.), **Group 2:** CH--S (i.v.), **Group 3:** CH--PLGA--NPs (i.n.), **Group 4:** CH--PLGA--NPs (i.v.), **Group 5:** CS-coated--CH--PLGA--NPs (i.n.), and **Group 6:** CS-coated--CH--PLGA--NPs (i.v.), with a dose CH = 10.0 mg/kg body weight. Four rats were taken for each sampling time of all six groups. The blood was collected and then the rats were sacrificed with immediate removal of the brains and lungs for each sampling time of all six groups, followed by preparation of the lungs or brain homogenate. For the extraction of different matrixes, we applied the same procedure mentioned above in the extraction of different sections of matrix samples for the bioanalysis and PK analysis. All the test samples were collected at different sampling time point intervals, such as 0.00 h (pre-dose without treated), followed by treated samples (0.50, 1.00, 2.00, 4.00, 8.00, 12.00, and 24.00 h). These collected samples were processed as mentioned above and then analyzed by the in-house bioanalytical method for quantification of half-life, K~e~, C~max~, and AUC~0--t~. A total of 32 rats were for each group (4 × 8 = 32) and the total number of rats for the whole PK study was 192 (32 rats for every group × 6 groups = 192), which were also given a dose as mentioned above. The blood of four rats from each group was collected, and then the rats were scarified, followed by immediate removal of the brains and lungs. The homogenate was prepared for all samples separately and analyzed by the in-house bioanalytical method \[[@B46-pharmaceutics-12-00203]\].

2.12. Pharmacodynamic Activity {#sec2dot12-pharmaceutics-12-00203}
------------------------------

### 2.12.1. Seizures Developed by PTZ {#sec2dot12dot1-pharmaceutics-12-00203}

The dose for each rat based their body weight (70.0 mg/kg PTZ) was given intra-peritoneal, and they were observed for half an hour for myoclonic jerks as well as for clonic generalized seizures, which were noted \[[@B21-pharmaceutics-12-00203],[@B47-pharmaceutics-12-00203]\]. For the development of PTZ seizure, we divided the rats into four groups as follows: **Group 1** (normal saline treated/control group), **Group 2** (catechin hydrate simple suspension treated), **Group 3** (CH--PLGA--NPs treated), and **Group 4** (CS-coated--CH-loaded--PLGA--NPs treated).

### 2.12.2. Seizures Developed by ICES {#sec2dot12dot2-pharmaceutics-12-00203}

For the ICES seizure development, we used and modified the Kitano et al. and Ahmad et al. method \[[@B21-pharmaceutics-12-00203],[@B48-pharmaceutics-12-00203]\] to see the effects of CH. In brief, the electroshock (2.0 mA current) was initially as a single train of pulse (20.0 Hz square wave for 0.20 s) to each rat by the ears electrodes, in which the electroshock intensity was enhanced linearly as 2.0 mA/2.0 s. The tonic hind limb extension (HLE) point came and the intensity of the current, that is, the seizure threshold current (STC), was noted. Additionally, tonic HLE was applied up to a current of 50.0 mA, and finally, the resulting electroshock was found. Finally, the cut-off current was noted and employed for analysis. The total of four groups of rats (6 × 4 = 24) were taken as **Group 1** (normal saline treated), **Group 2** (catechin hydrate simple suspension treated), **Group 3** (CH--PLGA--NPs treated), and **Group 4** (CS-coated--CH-loaded--PLGA--NPs treated).

2.13. Statistical Analysis {#sec2dot13-pharmaceutics-12-00203}
--------------------------

All the results were calculated statistically as mean ± SEM (standard error of mean). Student's *t*-test was applied to calculate the unpaired evaluations and their difference was investigated by analysis of variance (ANOVA) in the form of *p*--value.

3. Results and Discussion {#sec3-pharmaceutics-12-00203}
=========================

We selected a hydrophilic drug (catechin hydrate) to encapsulate into PLGA--NPs for this study. Optimized PLGA--NPs were characterized by the particle size, PDI, ZP, EE, DL, and process yield. The observed results indicated that the developed PLGA--NPs, via the double emulsification solvent evaporation method using central composite design software for the optimization of NPs, would be able to successfully encapsulate catechin hydrate for CNS delivery. On the basis of the optimized formula of optimized PLGA--NPs coated with CS to improve their mucoadhesive property and retention time in the nasal region. The developed CS-coated--CH-loaded--PLGA--NPs were further evaluated for CH release (in vitro), permeation study (ex vivo), and PK and PD study. Our results show that the developed CS-coated--CH-loaded--PLGA--NPs would be successfully coated on CH--PLGA--NPs for intranasal drug delivery systems.

3.1. Fitting the Model for Experimental Design and the Optimization of CH--PLGA--NPs {#sec3dot1-pharmaceutics-12-00203}
------------------------------------------------------------------------------------

CCD software predicted points were employed for the optimization of independent variables (PLGA, PVA, sonication time, and temperature to obtain the optimum size of particles with good PDI and Zeta potential ([Table 1](#pharmaceutics-12-00203-t001){ref-type="table"}). The experimental ranges for particle size, Y~1~ (36.00--549.67 nm); PDI, Y~2~ (0.063--0.711); and Zeta potential, Y~3~ (−8.12 to −33.54mV), are presented in [Table 2](#pharmaceutics-12-00203-t002){ref-type="table"}. We fed all the obtained data for the optimization of dependent variables (DV) into the CCD software which suggested optimized models in the form of polynomial quadratic (*p* \< 0.001) design. There were no significant data (*p* \< 0.050) found with a "lack of fit" for all three DV values. Predicted R^2^ values presented in [Table 2](#pharmaceutics-12-00203-t002){ref-type="table"} for all three DVs were in agreement with "adjusted R^2^ values". [Table 3](#pharmaceutics-12-00203-t003){ref-type="table"} shows the model fitting of all equations.

The individual interactive effect for X~1~ (PLGA in mg), X~2~ (%PVA), X~3~ (sonication time in seconds, and X~4~ (temperature, °C) on particle size is showed in [Table 1](#pharmaceutics-12-00203-t001){ref-type="table"} as Equation (5). It is evident from the equation that only temperature revealed a negative effect, while the other three showed positive effects; however, a positive effect on particle size (Y~1~) was observed with all three independent variables. Likewise, combination of independent variables showed a --ve effect for PLGA (mg) × %PVA (X~1~X~2~), PLGA (mg) × sonication time (X~1~X~3~), PLGA (mg) × temperature (°C) (X~1~X~4~), %PVA × sonication time (X~2~X~3~), %PVA × temperature (X~2~X~4~), and sonication time × temperature (X~3~X~4~), as presented in the three-dimensional plot for particle size range in [Figure 1](#pharmaceutics-12-00203-f001){ref-type="fig"}A to F. A gradual reduction in particle size was detected with an increase in sonication time, while a detrimental effect was observed for a decrease in the concentration of PLGA, and the % of PVA up to a certain limit in the formulation was observed upon a decrease in particle size diameter.

Likewise, a positive increase in PDI was determined with an enhancement in the sonication time, PLGA amount, % of PVA, and °C temperature in the formulation, as shown in Equation (6) and [Figure 2](#pharmaceutics-12-00203-f002){ref-type="fig"}A--F. Furthermore, a positive effect on PDI was revealed as a result of the combined effect of PLGA (mg) × temperature (°C) (X~1~X~4~) and %PVA × sonication time (X~2~X~3~), but more negative effects were observed from the combined effect of PLGA (mg) × %PVA (X~1~X~2~), PLGA (mg) × sonication time (X~1~X~3~), %PVA × temperature (X~2~X~4~), and sonication time × temperature (X~3~X~4~).

The effect on Zeta potential (mV) from independent variables is shown in Equation (7) and [Figure 3](#pharmaceutics-12-00203-f003){ref-type="fig"}A--F, whereby an optimization of Zeta potential was found with an increase in sonication time up to a certain limit, and but contrary results were shown with the amount of PLGA, %PVA, and temperature, that is, a decrease in their limits up to a certain point, which was not in favor of PDI. PLGA (mg) × temperature (°C) (X~1~X~4~), %PVA × sonication time (X~2~X~3~), PLGA (mg) × %PVA (X~1~X~2~), PLGA (mg) × sonication time (X~1~X~3~), %PVA × temperature (X~2~X~4~), and sonication time × temperature (X~3~X~4~), as collectively independent variables, exerted a positive magnitude, which proves a clear dominancy for sonication time on the amount of PLGA, %PVA, and temperature, and may be attributed to a decrease in particle size with lower PDI, thus favoring an optimum Zeta potential, owing to sonication time.

Constraints were used for independent variables to achieve an optimized formulation ([Table 1](#pharmaceutics-12-00203-t001){ref-type="table"} and [Table 4](#pharmaceutics-12-00203-t004){ref-type="table"}), whereas the independent variables (temperature) were kept in the range followed by the sonication time minimized within the range, whereas constraint applied for the amount of PLGA and %PVA was "minimized". On the other hand, in between all the dependent variables, "minimize" was marked for particle size with PDI and "maximize" was labeled for Zeta potential.

On the basis of the constraints and quadratic equations for three dependent variables, optimized PLGA--NPs were predicted by CCD with a final composition as follows: PLGA (50.0 mg), 1.10% PVA, 90 s sonication time, and 25 °C temperature ([Table 4](#pharmaceutics-12-00203-t004){ref-type="table"}).

CCD software suggested the final composition for optimized PLGA--NPs as follows: PLGA (50.0 mg), 1.10% PVA, 90 s sonication time, and 25.0 °C temperature, which was based on the constraints and quadratic equations for three DVs ([Table 4](#pharmaceutics-12-00203-t004){ref-type="table"}). Furthermore, the particle size (93.46 nm), PDI (0.106), and Zeta potential (−12.63 mV) with desirability of 0.9938 were suggested for the optimized CH--PLGA--NPs. Optimized CH--PLGA--NPs were formulated on the basis of the experimental level of nanoformulations to validate their particle size (nm), %PVA, and Zeta potential (mV), as presented in [Table 4](#pharmaceutics-12-00203-t004){ref-type="table"} and [Figure 4](#pharmaceutics-12-00203-f004){ref-type="fig"}A,B.

For the improvement of brain bioavailability for antiepileptic efficiency, the uptake of cells was increased by the preparation of coating with chitosan on optimized CH--PLGA--NPs in different %age CS concentrations, as shown in [Table 5](#pharmaceutics-12-00203-t005){ref-type="table"}. A modified and previously reported Ahmad et al., 2017b CS-coating technique for the preparation of CS-coated--optimized CH--PLGA--NPs to the brain targeted CH delivery. All the coated NPs were characterized on the basis of ZP, PDI with their particle size range in which all the particles were observed \<200.0 nm, and smallest PDI (\<0.380) ([Table 5](#pharmaceutics-12-00203-t005){ref-type="table"}). In addition, the ultrasonication process helped to reduce the size of the particles at the nanometer-size range with a narrow PDI. The sizes of the PLGA--NPs were measured as 93.46 ± 3.94 nm, where loading of the catechin hydrate did not show any significant increase in size of the NPs. However, the initial particle size for optimized CH-loaded--PLGA--NPs was 93.46 ± 3.94 nm, which was significantly increased to 106.31 ± 2.91 nm and 142.43 ± 3.94 nm after application of a different percentage (2% and 4%) of CS-coating on the CH--PLGA--NPs ([Table 5](#pharmaceutics-12-00203-t005){ref-type="table"}, [Figure 4](#pharmaceutics-12-00203-f004){ref-type="fig"}C) \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\]. As reported before, the particle size was increased slightly owing to the coating of a high molecular weight of CS on PLGA \[[@B28-pharmaceutics-12-00203],[@B49-pharmaceutics-12-00203]\]. In addition, an enhancement of the particle size owing to CS-coating on NPs was also seen. On the other hand, this enhancement of the particle size may be because of a greater amount of polymer addition via CS-coating \[[@B50-pharmaceutics-12-00203]\]. Furthermore, the amount of polymer was increased, which produced a more viscous dispersed phase. Therefore, it resulted in an increase in the particle size for NPs \[[@B51-pharmaceutics-12-00203]\]. PDI produced a value \<0.380, which means the distribution of particle size inside the suspension is lower, while ZP gave values of 21.64 ± 1.04 and 24.34 ± 1.59 mV for 2% and 4% CS-coating on CH--PLGA--NPs, respectively ([Figure 4](#pharmaceutics-12-00203-f004){ref-type="fig"}D). When CS was coated on CH--PLGA--NPs, a +ve ZP was produced because of the presence of the amine group in the CS structure \[[@B52-pharmaceutics-12-00203],[@B53-pharmaceutics-12-00203]\]. However, in all cases, formulated nanoparticles were recorded with \<0.380 PDI, indicating the monodisperse nature of the nanoparticles. The surface charge of the formulated PLGA NPs was found to be almost constant, near to slightly negative (−12.63 ± 0.08 mV, [Figure 4](#pharmaceutics-12-00203-f004){ref-type="fig"}B, for CH--PLGA--NPs). Coating of the NPs, in comparison, showed a significant alteration of the surface charge towards a positive scale to 21.64 ± 1.04 and 24.34 ± 1.59 mV for 2% and 4% CS coating on CH--PLGA--NPs, respectively \[[@B53-pharmaceutics-12-00203]\].

PLGA was used as a polymer to formulate the polymeric nanoparticles, whereas PVA was incorporated to stabilize the formulation. PVA is a widely used stabilizer to formulate PLGA NPs \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\], where the binding of PVA with PLGA is facilitated by the interpenetration of PLGA and PVA molecules during the development of NPs. Being a copolymer, PVA consists of poly(vinyl alcohol) and poly(vinyl acetate), with the characteristics of a block copolymer, where the vinyl part displays a hydrophobic nature. This hydrophobic segment of PVA is known to penetrate the organic phase during formulation development, while removal of organic solvent from the polymeric matrix results in entrapment of the PVA segment within the PLGA polymeric matrix \[[@B54-pharmaceutics-12-00203]\]. Ultrasonication of the course emulsion reduced the size of the dispersed phase, and thereby the particles of the nanocarrier were found to be uniform in characteristics, within the size range of 93.46 ± 3.94 nm. Selection of CH and polymer contents with proper control of processing parameters was conducted as described in our previous articles \[[@B28-pharmaceutics-12-00203],[@B54-pharmaceutics-12-00203]\], and during the formulation development of CH-loaded PLGA NP, we were able to obtain the size of the optimized particles with the desired mean diameter. The PDIs of the formulations are found to be low, and thus did not show any variations in batches prepared during the entire research period, indicating the formation of unimodal particles. Coating of the particles with CS has shown a significant (*p* \< 0.05) increase in the size of the particles; however, such a change in size did not alter the mean PDI when compared with uncoated particles, which indicates that the process of formulation development does not result in agglomeration of the particles after CS coating.

3.2. %EE and %DL Examination {#sec3dot2-pharmaceutics-12-00203}
----------------------------

The average particle size with PDI at different compositions of PLGA polymer is presented in the [Table 2](#pharmaceutics-12-00203-t002){ref-type="table"}. However, the optimized CH PLGA NPs and 2% CS coated optimized CH--PLGA--NPs were 93.46 ± 3.94 nm and 106.31 ± 2.91 nm in particle size, with −12.63 ± 0.08 mV and 21.64 ± 1.04 mV ZP, respectively. Finally, the concentrations of PLGA polymer showed a small impact on the amount of CH entrapment for NPs. CH-loaded--PLGA--NPs showed a maximum %EE with the developed NPs of 2% and 4% CS-coated, equal to 80.36 ± 4.01% and 81.66 ± 4.61%, with an optimal %DL, that is, 5.98 ± 0.36% and 6.87 ± 0.49%, respectively. The effects of %EE and %DL of polymers on CS-coated-opt-CH--PLGA--NPs were also shown, as presented in [Table 5](#pharmaceutics-12-00203-t005){ref-type="table"}. In addition, %EE and %DL were dependent on the percentage use of polymer, which resulted in an enhancement in %EE from 80.36 ± 4.01% to 81.66 ± 4.61%, as well as in %DL from 5.98 ± 0.36% to 6.87 ± 0.49%, for 2% and 4% CS-coating on PLGA NPs, respectively. CS--CH--PLGA--NPs displayed significantly maximum percentages of DL and EE when compared with other types of NPs formulations. In this way, we can characterize the presence of PVA and the surface of CS on the NPs.

Finally, it is concluded that CH adsorbed the surface of NPs because of the electrostatic interaction between positively-charged chitosan and negatively-charged hydroxyl (--OH) of CH \[[@B28-pharmaceutics-12-00203],[@B45-pharmaceutics-12-00203]\]. A 21.64 mV ZP has the stability of the optimized CS--CH--PLGA--NPs ([Figure 4](#pharmaceutics-12-00203-f004){ref-type="fig"}D). CS--CH--PLGA--NPs present a +ve charge on their surface, which helps the mucoadhesion, and an extended residence time, followed by the reduction of mucociliary clearance of optimized NPs from the nasal-mucosa \[[@B27-pharmaceutics-12-00203],[@B28-pharmaceutics-12-00203]\].

3.3. Determination of Outer Surface Texture of NPs' Analysis {#sec3dot3-pharmaceutics-12-00203}
------------------------------------------------------------

In all cases of CH-loaded NPs tested for morphology and the morphological evaluation, spherical particles with a smooth surface are indicated, as depicted in the SEM and TEM micrographs ([Figure 5](#pharmaceutics-12-00203-f005){ref-type="fig"}). PLGA NPs can be aggregated owing to the process of drying with their maximum surface energy. The size of NPs was analysed by DLS technology, whereas the real diameter of NPs after drying was analysed by TEM and SEM. Spherical-shaped CS--CH--PLGA--NPs were shown by TEM ([Figure 5](#pharmaceutics-12-00203-f005){ref-type="fig"}B). TEM microscopic viewfinder was divided into four quadrants and analysed all the particles size ranges, that is, less than 110.0 nm. All the determinations were found to be approximately the same as each other.

3.4. Differential Scanning Calorimetry (DSC) {#sec3dot4-pharmaceutics-12-00203}
--------------------------------------------

The DSC thermograms of pure catechin (CH); polymer (PLGA); polyvinyl alcohol (PVA); a physical mixture of CH, PVA, and PLGA; freeze-dried CH--loaded--optimized polymer (PLGA)--NPs; pure chitosan; and CS-coated--CH-loaded--optimized polymeric PLGA--NPs, respectively, are represented in [Figure 6](#pharmaceutics-12-00203-f006){ref-type="fig"}. (+)-Catechin presents two peaks in the temperature range of 75--150 °C linked to water loss, and an endothermic peak at 175.3 °C linked to anhydrous catechin melting, which is very close to or the same as the reported melting point of 175.0 °C, followed by its decomposition above 200 °C. Similarly, the physical mixture of CH, PVA, and PLGA exhibited the characteristic peaks of all of these. However, the CH sharp peak was absent in CH-loaded--PLGA--NPs. This indicates that catechin was completely entrapped in the CH-loaded--PLGA--NPs. A broad peak of PLGA and PLGA--NPs was shown between 45 and 55 °C ([Figure 6](#pharmaceutics-12-00203-f006){ref-type="fig"}) \[[@B28-pharmaceutics-12-00203],[@B54-pharmaceutics-12-00203]\]. DSC thermogram of CS gave an exothermic broad peak at 311.5 °C, which appeared again in DSC thermograms of CS-coated CH-loaded--PLGA--NPs at 311.7 °C. The chitosan peak was recognized again in the thermogram of the CS-coated--PLGA--NPs ([Figure 6](#pharmaceutics-12-00203-f006){ref-type="fig"}), because that coated on the PLGA--NPs and one smaller peak of PLGA at 52.5 °C also shown, possibly owing to the smaller %CS amount, correlate to that percentage of PLGA, but the CH--DSC thermogram peak was also absent in the CS--CH--PLGA--NPs ([Figure 6](#pharmaceutics-12-00203-f006){ref-type="fig"}) \[[@B28-pharmaceutics-12-00203],[@B54-pharmaceutics-12-00203]\].

3.5. ATR Analysis Based on FTIR {#sec3dot5-pharmaceutics-12-00203}
-------------------------------

Pure catechin hydrate (CH), PVA, PLGA--NPs, CH-loaded--PLGA--NPs, chitosan, and chitosan-coated--CH-loaded--PLGA--NPs were evaluated via FTIR spectrophotometer, which is presented in [Figure 7](#pharmaceutics-12-00203-f007){ref-type="fig"}. Pure catechin hydrate (CH), PVA, PLGA--NPs, CH-loaded--PLGA--NPs, chitosan, and chitosan-coated--CH-loaded--PLGA--NPs were evaluated via ATR. ATR is a tool that works on the basis of FT-IR technology, in which our optimized NPs' surfaces can be analysed qualitatively or quantitatively \[[@B54-pharmaceutics-12-00203]\]. Characteristic IR peaks of catechin were observed at 3341.23 (phenolic hydroxyl group), 1608.75, 1519.29, 1458.83, (phenyl ring), 1143.96, and 1027.99 (stretching vibration of C--O--C) cm^−1^. The PLGA spectrum displayed stretching peaks of --C=O at 1746.53 cm^−1^ and C--H bending at 850--1470 cm^−1^. PLGA responded at 2950.22 cm^−1^ owing to the linear CH~2~ stretching and at 1746.53 cm^−1^ owing to the ester bond. For PVA, the characteristic absorption peaks are at 3313.52 cm^−1^ (O--H stretching), 2936.09 cm^−1^ (asymmetric stretching of CH~2~), 2911.57 cm^−1^ (symmetric stretching of --CH~2~), 1567.93 cm^−1^ (owing to water absorption), 1427.11 cm^−1^ (--CH~2~ bending), 1321.16 cm^−1^ (δ (OH), rocking with CH wagging), 1087.92 cm^−1^ (--C--O stretching with --OH bending) (PVA amorphous sequence), 945.48 cm^−1^ (--CH~2~ rocking), and 842.76 cm^−1^ (stretching of C--C). CH--PLGA--NPs achieved all the distinctive peaks of PLGA--NPs. However, the CH-distinctive peak inside the CH-loaded--PLGA--NPs showed the diminished peaks. All these nanomaterial surfaces data for optimized NPs were analysed by ATR technology. On the basis of the evaluation of these results, it was concluded that CH was present inside the core of CH PLGA NPs. ATR spectra of CS showed a distinctive band at 3376.71 cm^−1^, that is, a clear indication of an N--H bond overlapped with O--H bond streching. The C--H stretching-vibration and N--H bending-vibration were designated at 2891.36 cm^−1^ and 1651.44 cm^−1^, respectively. The characteristic peaks of the catechin and CS-coated--CH-loaded--PLGA--NPs were present in the spectrum with no extra peaks for their opposite interaction. However, in the case of CS-coated--CH-loaded--PLGA--NPs, the peaks of the catechin were indicated to be diminished, representing a small interaction between the catechin and the polymer; thus, catechin hydrate presence inside the core of NPs can be recommended ([Figure 7](#pharmaceutics-12-00203-f007){ref-type="fig"}) \[[@B54-pharmaceutics-12-00203]\].

3.6. In Vitro CH Release Evaluation {#sec3dot6-pharmaceutics-12-00203}
-----------------------------------

CH was released as a cumulative pattern for CH--S, that is, 87.63 ± 3.98%, and CH--PLGA--NPs, that is, 67.28 ± 5.03%, in addition to biodegradable polymeric, that is, CS--CH--PLGA NPs, 81.34 ± 4.02 in 1 to 24 h, correspondingly ([Figure 8](#pharmaceutics-12-00203-f008){ref-type="fig"}A). CS--CH--PLGA--NPs exhibited a biphasic release as follows: 40.11 ± 3.21% drug release in the initial 2 h, followed by a sustained release for the remaining CH; this burst release behavior may be because of more solubility in dissolution media along with a quick release of the drug from the NPs' surface (drug present more at the surface of NPs). CS-coated NPs released a biphasic CH release pattern like 40.11 ± 3.21% initially up to 2.0 h, after which it showed a sustained release pattern for the remaining percentage of CH. The burst release pattern may be the result of the presence of a higher quantity of CH on the NPs' surface. This allows fast release from the highest % solubility in dissolution media. The most important part here is that CH was encapsulated inside the core of NPs, which showed a sustained release pattern. The maximum crystalline nature of PLGA NPs' structure and smaller PVA permeability of water were most important for the smaller rate of degradation with their sustained release of CH \[[@B28-pharmaceutics-12-00203],[@B53-pharmaceutics-12-00203]\]. On other side, if CS was added to coat on the NPs, CH enhanced the rate of slow release, which can be indicated by the higher permeability of water via the CS surface \[[@B34-pharmaceutics-12-00203]\]. CH was released at a maximum via optimized NPs containing hydrophilic glycolide units of PLGA--NPs, which enhanced the release up to 12.0 h, after which CH was released in a sustained form. The hydrophilic nature of PLGA was enhanced, which is responsible for the enhancement of water permeability of optimized NPs' surface, resulting in an enhanced quantity of CH release \[[@B28-pharmaceutics-12-00203],[@B54-pharmaceutics-12-00203]\]. Furthermore, PLGA showed smaller hydrophilicity in comparison with CS, which produces a higher hydration of optimized NPs' matrix, and thus a maximum quantity of CH was released \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203],[@B54-pharmaceutics-12-00203]\].

3.7. A Permeation (Ex Vivo) Evaluation via Nasal Mucosa {#sec3dot7-pharmaceutics-12-00203}
-------------------------------------------------------

Pure CH--S showed less permeation compared with CH PLGA NPs and CS--CH--PLGA NPs ([Figure 8](#pharmaceutics-12-00203-f008){ref-type="fig"}B). The permeation profile was found to be more significant for CS--CH--PLGA NPs (*p* \< 0.001) compared with CS--CH--PLGA NPs (*p* \< 0.01) and CH--S. This means CS--CH--PLGA NPs increased the permeation activity of CS. The permeation was found to be highest with \>83.64 ± 5.33% in 24.0 h for CS--CH--PLGA NPs, whereas CH--PLGA--NPs and CH--S were only 68.64 ± 4.66% and 20.34 ± 2.99%, respectively ([Figure 8](#pharmaceutics-12-00203-f008){ref-type="fig"}B). Catechin hydrate improved their permeation because of the positively-charged --NH~2~--group on the CS carbon two-position, which interacted with the negatively-charged cell membranes. Similarly, mucosal epithelial cells were responsible for their tight junction mechanism endorsement \[[@B28-pharmaceutics-12-00203]\]. Pure CH--S has much less permeability owing to their hydrophilic nature, which is a strong justification. The lipophilic nature of drugs has a higher permeability via skin or nasal mucosa, as stated by Richter and Keipert \[[@B55-pharmaceutics-12-00203]\]. CS--CH--PLGA NPs with hydrophobic surface and particle size \<200 nm size easily penetrate the biological membrane. At this time, we concluded on the basis of the above results that, as they contain the smallest size of NPs with maximum percentage yield and optimal % of EE plus LC, which is responsible for the higher permeation profile, the CS--CH--PLGA--NPs will give better results for in vivo activity.

3.8. Bioanalysis by UHPLC/MS/MS {#sec3dot8-pharmaceutics-12-00203}
-------------------------------

[Figure 9](#pharmaceutics-12-00203-f009){ref-type="fig"} and [Figure 10](#pharmaceutics-12-00203-f010){ref-type="fig"} exhibit MS and MS/MS scans of CH and IS MS and MS/MS spectra of CH at the time of method development. The developed chromatograms of different matrixes are shown in [Figure 11](#pharmaceutics-12-00203-f011){ref-type="fig"}A,B; extracted plasma and brain homogenate (BH) of CH are shown in [Figure 11](#pharmaceutics-12-00203-f011){ref-type="fig"}C,D; followed by extracted plasma and BH of quercetin shown in [Figure 11](#pharmaceutics-12-00203-f011){ref-type="fig"}E,F. Mean recovery of CH from BH and plasma (*n* = 6) was shown to be \>80.17%. All proposed matrixes of CH showed an excellent linearity with a range 1.0--1000 ng/mL, that is, *r*^2^ \> 0.998. Further, LOD and LOQ were found to be 0.894 and 1.00 ng/mL, respectively. The selectivity of all developed chromatograms for all different matrixes of CH was proven. (Coefficient of variation) %CV (0.72--3.81%, 0.39--4.90%, and 0.59--4.08%) was found, whereas the % accuracy (97.03--99.41%, 93.07--98.62%, and 96.04--98.71%) is exhibited for brain homogenate (BH), Plasma PL, and lungs homogenate (LH) of all QCs in [Table 6](#pharmaceutics-12-00203-t006){ref-type="table"}. All the different QC levels stabled in different storage conditions like freeze thaw, long-term, post-processing, and bench-top are displayed in [Table 7](#pharmaceutics-12-00203-t007){ref-type="table"} \[[@B28-pharmaceutics-12-00203],[@B56-pharmaceutics-12-00203],[@B57-pharmaceutics-12-00203]\]. For the validation of parameters calculations, we used the formulas mentioned in [Table 8](#pharmaceutics-12-00203-t008){ref-type="table"}.

3.9. Evaluation of PK Parameters {#sec3dot9-pharmaceutics-12-00203}
--------------------------------

The compared PK parameters including C~max~ and T~max~ exhibited brain CH concentration versus time for single i.v. and i.n. doses of CH--S, CH--PLGA--NPs, and CS--CH--PLGA--NPs in Wistar rats, while the trapezoidal method was used ([Figure 12](#pharmaceutics-12-00203-f012){ref-type="fig"}). For CH--S, C~max~ of 44.23 ± 7.04 (i.v.) and 81.68 ± 10.13 ng/mL (i.n.) was found; for CH--PLGA--NPs, an enhanced C~max~ of 98.36 ± 19.55 ng/mL (i.v.) and 623.36 ± 24.21 ngmL^−1^ (i.n.) was found; while for CS--CH--PLGA--NPs, an enhanced C~max~ of 126.48 ± 17.61 ngmL^−1^ (i.v.) and 996.24 ± 44.24 ngmL^−1^ (i.n.) was exhibited (\* *p* \< 0.1, \*\* *p* \< 0.01, and \*\*\* *p* \< 0.001) ([Table 9](#pharmaceutics-12-00203-t009){ref-type="table"}). Therefore, a elevated i.n. AUC~0--t~ (977.32 ± 33.14 ng h/mg) for CH--S, AUC~0--t~ (7785.90 ± 83.64 ng h/mg) for CH--PLGA--NPs, and AUC~0--t~ (12,444.50 ± 139.25 ng h/g) for CS--CH--PLGA--NPs was observed (\* *p* \< 0.1, \*\* *p* \< 0.01, and \*\*\* *p* \< 0.001), respectively, for highly significant data of CS--CH--PLGA--NPs as compared with CH--S by i.n., as a result of the enhanced C~max~ with the delayed elimination rate. Likewise, comparative bioavailability of CS--CH--PLGA--NPs, CH--PLGA--NPs, and CH--S was enhanced for the brain when we applied statistics for i.n. application. There is a clear indication of nose to brain targeting, as reported in the previous research study \[[@B28-pharmaceutics-12-00203],[@B34-pharmaceutics-12-00203],[@B54-pharmaceutics-12-00203]\].

Release of the entrapped therapeutic agent (CH) from the colloidal delivery system is highly necessary to produce the intended physiological response, where this release can effectively be modulated through alteration of the physicochemical characteristics of the medium. As the formulated CS-coated CH--PLGA is intended to deliver the entrapped drug inside the brain by the i.n. route, the release study of the formulations was performed at pH = 7.4, which approximately corresponds to the pH of the brain cellular compartments. A biodegradable polymer released a drug, for example, CH, by various mechanisms: polymeric pores re-adsorbed on their surface, diffusion, CS-coated--PLGA NPs desorbed on their surface, or degradation and erosion of polymeric surface (Md et al., 2013). CS-coated--PLGA NPs released CH very fast at first, that is, 28.64% in 1.0 h, and afterwards released it in a sustained manner up to 24.0 h. On the other side, CH--S released very fast, that is, 87.63% up to 1.0 h, but in the case of CS-coated--PLGA NPs, CH was released very fast at first owing to the burst release, and after that, CH was released in a sustained manner from the outer surface of optimized NPs ([Figure 8](#pharmaceutics-12-00203-f008){ref-type="fig"}A).

Bioavailability of the brain increased via the burst release of CH from CS-coated--PLGA NPs to produce CH for epilepsy treatment. The Higuchi model showed r^2^ = 0.986 for kinetic release, which also gave a clear indication that CH was released through the diffusion and swelling methods in a controlled manner \[[@B58-pharmaceutics-12-00203]\]. Goat nasal mucosa was used for CH permeation study of CS-coated--PLGA NPs (\<0.001) as compared with CH--PLGA NPs (\<0.01) and pure-CH--S, which showed higher enhancement of CH permeation by CS-coating \[[@B34-pharmaceutics-12-00203]\]. Higher permeation of CS CH--PLGA NPs was found because of the smaller size of NPs as well as the interaction of the --NH~2~ group of CS containing a +ve charge and nasal mucosa containing a --ve charge on their surface \[[@B27-pharmaceutics-12-00203]\]. CS contained an oligosaccharide chain of mucin that showed mucoadhesive nature of CS without the loaded drug and CS CH--PLGA NPs. CS-mucoadhesive potency is more suitable relative to others owing to the interaction of CS, that is, the mucin content is much higher \[[@B27-pharmaceutics-12-00203]\].

3.10. Evaluation of Epilepsy Treatment {#sec3dot10-pharmaceutics-12-00203}
--------------------------------------

### 3.10.1. Catechin Hydrate Effect on ICES Test {#sec3dot10dot1-pharmaceutics-12-00203}

The selected dose of 10.0 mg kg^--1^ b. wt. taken for CS CH--PLGA NPs (*p* \< 0.001) and CH PLGA NPs (*p* \< 0.01) was highly significant at the time of ICES evaluation as compared with CH-S, as on the other side, a highly significant protection (*p* \< 0.001, *p* \< 0.01, and *p* \< 0.05) correspondingly was also found when compared with the normal saline group, that is, the control ([Figure 13](#pharmaceutics-12-00203-f013){ref-type="fig"}).

### 3.10.2. Treatment of PTZ-Induced Seizures Evaluation by Catechin Hydrate {#sec3dot10dot2-pharmaceutics-12-00203}

PTZ was injected initially on fore- and hind-limb myoclonic jerks (60 to 70 s), which results in generalized clonic seizures produced on one side of the back. The selected doses of 10.0 mg kg^−1^ b. wt. of CS coated--CH--PLGA NPs and CH--PLGA NPs were found to offer more significant protection (*p* \< 0.001 and *p* \< 0.01) with the decrement of the onset of myoclonic jerks, followed by clonic generalized seizures when compared with CH--S ([Figure 13](#pharmaceutics-12-00203-f013){ref-type="fig"}). In our study, the CS-coated--CH--PLGA--NPs applied and illustrated better future treatment of antiepileptic activity at smaller doses of catechin hydrate, that is, 10.0 mg kg^−1^ b. wt. in comparison with CH--S for ICES \[[@B21-pharmaceutics-12-00203]\]. Furthermore, CS-coated--CH--PLGA--NPs showed a higher protective effect against PTZ-induced seizures, as compared with CH--PLGA NPs and CH--S. This is a great finding reported previously by Bonnet et al. and then by Vyas et al. \[[@B8-pharmaceutics-12-00203],[@B59-pharmaceutics-12-00203]\], in which they showed a great suppression of bioelectric and epileptic activities, that is, induction by bicuculline, caffeine, or zero-Mg.

The aforementioned observations can be concluded as follows: catechin hydrate as a CS-coated--CH--PLGA--NPs, when applied via the i.n. route, reaches the brain with maximum effectiveness, as compared with CH--PLGA--NPs and free CH when administered intranasally. There are many studies in the literature in favor of the i.n. route as the most effective route, in which they have mentioned that Lamotrigine, Clonazepam, Diazepam, and Midazolam loaded with mucoadhesive nanoformulation increased their effective treatment of the mentioned drugs for anticonvulsant activity \[[@B59-pharmaceutics-12-00203],[@B60-pharmaceutics-12-00203],[@B61-pharmaceutics-12-00203]\].

4. Conclusions {#sec4-pharmaceutics-12-00203}
==============

CH-loaded--PLGA--NPs were formulated by the double emulsion-solvent evaporation method and optimized using a four-factor, three-level central composite design. The optimized PLGA--NPs were optimized on the basis of particle size, PDI, and ZP with the help of CCD. The optimized PLGA--NPs showed a smaller particle size, smaller PDI, and optimum Zeta potential, with higher entrapment efficiency, CH loading, and a high process yield following CS-coating. The CS--CH--PLGA--NPs showed a sustained release profile over 24.0 h with higher nasal permeation and prolonged retention for nose-to-brain delivery, and avoided hepatic first pass metabolism. The positive Zeta potential indicated the stability of CS--CH--PLGA--NPs owing to the presence of CS. A smooth surface of NPs was more authenticated via SEM and TEM, followed by DSC and FTIR studies exhibiting an entrapment of CH inside the optimized NPs. CS--CH--PLGA--NPs effectively crossed the BBB and also treated the epilepsy at smaller doses via the i.n. route as compared with CH--PLGA--NPs and pure CH--S. The developed UPLC-ESI-triple-quadrupole-MS/MS method was validated and used successfully for PK and biodistribution studies of optimized CS--CH--PLGA--NPs. Finally, the application of CS--CH--PLGA--NPs in the PTZ and ICES epilepsy model showed CS--CH--PLGA--NPs to be a novel, effective, and safe brain-targeted delivery system for the treatment of epilepsy.
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![Response surface plot showing the effect of independent variables on particle size. PVA, PLGA. (**A**). Particle size, PLGA, sonication time; (**B**). Particle size, PLGA, temperature; (**C**). Particle size, PVA (%), sonication time; (**D**). Particle size, PVA (%), temperature (°C); (**E**). Particle size, PVA (%), temperature (°C); (**F**). Particle size, sonication time, temperature (°C).](pharmaceutics-12-00203-g001){#pharmaceutics-12-00203-f001}

![Response surface plot showing the effect of independent variables on polydispersity index (PDI), PLGA, PVA (%); (**A**). PDI, PLGA, sonication time; (**B**). PDI, PLGA, temperature; (**C**). PDI, PVA (%), sonication time; (**D**). PDI, PVA (%), temperature; (**E**). PDI, temperature, sonication time; (**F**). PDI, temperature, sonication time.](pharmaceutics-12-00203-g002){#pharmaceutics-12-00203-f002}

![Response surface plot showing the effect of independent variables on Zeta potential (ZP). (**A**). Zeta potential, PVA (%), PLGA; (**B**). Zeta potential, sonication time, PLGA; (**C**). Zeta potential, temperature (°C), PLGA; (**D**). Zeta potential, sonication time, PVA (%); (**E**). Zeta potential, temperature, PVA (%); (**F**). Zeta potential, temperature, sonication time.](pharmaceutics-12-00203-g003){#pharmaceutics-12-00203-f003}

![Dynamic light scattering techniques for determining the particle size distribution of CH-loaded--PLGA--NPs' globule size (**A**) and Zeta potential (**B**), as well as CS-coated--CH-loaded--PLGA--NPs' particle size (**C**) and zeta potential (**D**) images.](pharmaceutics-12-00203-g004){#pharmaceutics-12-00203-f004}

![Scanning electron microscopy (SEM) (**A**) and transmission electron microscopy (TEM) (**B**) images of CS-coated--CH-loaded--PLGA--NPs.](pharmaceutics-12-00203-g005){#pharmaceutics-12-00203-f005}

![The differential scanning calorimetry (DSC) thermograms of pure catechin (CH); polymer (PLGA); polyvinyl alcohol (PVA); a physical mixture of CH, PVA, and PLGA; freeze-dried CH-loaded--optimized polymeric (PLGA)--NPs; pure chitosan; and CS-coated--CH-loaded--optimized polymeric PLGA--NPs.](pharmaceutics-12-00203-g006){#pharmaceutics-12-00203-f006}

![Different Fourier transform infrared spectroscopy (FTIR) spectra with an attenuated total reflection (ATR) attachment of pure catechin hydrate (CH), PVA, PLGA--NPs, CH-loaded--PLGA--NPs, chitosan, and chitosan-coated--CH-loaded--PLGA--NPs.](pharmaceutics-12-00203-g007){#pharmaceutics-12-00203-f007}

![(**A**) In vitro release profile of CS--S, CH-loaded--PLGA--NPs, and chitosan-coated--CH-loaded--PLGA--NPs performed using the dialysis bag method, revealing the sustained release pattern of CH-loaded--PLGA--NPs and Chitosan-coated--CH-loaded--PLGA--NPs (mean ± SD, *n* = 3). (**B**) Ex vivo permeation profiles of developed chitosan-coated--CH-loaded--PLGA--NPs as compared with CH-loaded--PLGA--NPs and pure CH--S through goat nasal mucosa.](pharmaceutics-12-00203-g008){#pharmaceutics-12-00203-f008}

![Mass spectrum of (**A**) catechin hydrate (CH) parent ion (protonated precursor \[M--H\]^−^ ions at m/z 289.23) and (**B**) catechin hydrate (CH) product ion (major fragmented product ion at m/z 245.20) showing fragmentation transitions.](pharmaceutics-12-00203-g009){#pharmaceutics-12-00203-f009}

![Mass spectrum of, (**A**) quercetin (IS) precursor ion (protonated precursor \[M--H\]^−^ ions at m/z 301.21 and (**B**) internal standard (IS) product ion (major fragmented product ions at m/z 151.21) showing fragmentation transitions.](pharmaceutics-12-00203-g010){#pharmaceutics-12-00203-f010}

![Typical chromatograms of extracted blank plasma (**A**), extracted blank brain homogenate (**B**), plasma extracted catechin hydrate (CH) (**C**), extracted brain homogenate catechin hydrate (CH) (**D**), plasma extracted quercetin (IS) (**E**), and extracted brain homogenate quercetin (IS) (**F**).](pharmaceutics-12-00203-g011){#pharmaceutics-12-00203-f011}

![Pharmacokinetic profiles of catechin hydrate (CH) concentration in the brain at different time intervals after administration of optimized different nanoformulations compared with pure catechin hydrate (CH).](pharmaceutics-12-00203-g012){#pharmaceutics-12-00203-f012}

![Effect of different nanoformulations of catechin hydrate on pentylenetetrazole (PTZ)-induced latency to generalized seizures (**A**), myoclonic jerks (**B)**, % against mortality owing to PTZ-induced seizures (**C**), increasing current electroshock (ICES)-induced threshold for HLTE (**D**), ICES-induced post-HLTE recovery time (**E**), and % protective effect of different nanoformulations of catechin hydrate against ICES-induced mortality in rats (**F**). \*\*\* (*p* \< 0.001), \*\* (*p* \< 0.01), and \* (*p* \< 0.05).](pharmaceutics-12-00203-g013){#pharmaceutics-12-00203-f013}
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###### 

Variables in "Design Expert" software for the preparation and optimization of catechin hydrate (CH) PLGA--nanoparticles (NPs). PVA, polyvinyl alcohol; PDI, polydispersity index.

  ---------------------------- --------------------------- ---------------- ---------------
  **Factors**                  **Levels**                                   
  **Independent Variables**    **Low (−1)**                **Medium (0)**   **High (+1)**
  X~1~ = PLGA (mg)             50                          175              300
  X~2~ = PVA (%)               0.5                         2.0              4.0
  X~3~ = Sonication Time (s)   30                          150              300
  X~4~ = Temperature (°C)      20                          35               50
                               **Constraints**             **Importance**   
  **Independent Variables**                                                 
  X~1~ = PLGA (mg)             Minimize                    +  +  +  + + +   
  X~2~ = PVA (%)               Minimize                    +  +  +  +       
  X~3~ = Sonication Time (s)   Minimize within the range   \+ + + + + + +   
  X~4~ = Temperature (°C)      In range                    − − − − − −      
  **Dependent variables**                                                   
  Y~1~ = Particle size (nm)    Minimize                    +  +  +  +  +    
  Y~2~ = PDI                   Minimize                    +  +  +  +       
  Y~3~ = Zeta Potential (mV)   Maximize                    +  +  +  + +     
  ---------------------------- --------------------------- ---------------- ---------------

pharmaceutics-12-00203-t002_Table 2

###### 

Formulations recommended by "Design Expert" software, independent variables, and their responses.

  Formulation Code    Independent Variables   Dependent Variables                                                                                 
  ------------------- ----------------------- --------------------- ----- ---- ---------------- --------------- ---------------- -------- ------- ---------
  PLGA1               50                      0.5                   30    20   36.00 ± 2.01     0.063 ± 0.001   −8.12 ± 0.09     38.56    0.051   −38.53
  PLGA2               300                     0.5                   30    20   341.08 ± 11.01   0.394 ± 0.021   −31.09 ± 3.11    340.16   0.395   −31.13
  PLGA3               50                      4                     30    20   266.89 ± 7.35    0.412 ± 0.032   −28.43 ± 2.91    266.60   0.413   −28.36
  PLGA4               300                     4                     30    20   451.43 ± 18.54   0.506 ± 0.053   −30.18 ± 2.98    453.41   0.505   −31.08
  PLGA5               50                      0.5                   300   20   170.52 ± 4.27    0.316 ± 0.026   −21.42 ± 2.18    171.64   0.318   −21.50
  PLGA6               300                     0.5                   300   20   396.47 ± 13.54   0.539 ± 0.041   −27.35 ± 3.11    397.10   0.540   −27.13
  PLGA7               50                      4                     300   20   241.67 ± 7.84    0.394 ± 0.019   −24.51 ± 2.01    241.07   0.395   −24.87
  PLGA8               300                     4                     300   20   496.37 ± 19.64   0.643 ± 0.073   −32.64 ± 4.06    497.64   0.644   −32.62
  PLGA9               50                      1.1                   90    25   93.46 ± 3.94     0.106 ± 0.010   --12.63 ± 0.08   94.14    0.108   --12.61
  PLGA10              300                     0.5                   30    50   371.46 ± 12.64   0.367 ± 0.013   −28.45 ± 2.93    370.75   0.368   −28.43
  PLGA11              50                      4                     30    50   291.58 ± 8.64    0.423 ± 0.034   −26.47 ± 2.16    289.29   0.424   −26.45
  PLGA12              300                     4                     30    50   446.48 ± 19.31   0.583 ± 0.050   −27.94 ± 3.18    445.10   0.584   −27.91
  PLGA13              50                      0.5                   300   50   121.34 ± 3.59    0.416 ± 0.031   −19.34 ± 1.97    120.98   0.417   −19.31
  PLGA14              300                     0.5                   300   50   366.49 ± 12.26   0.411 ± 0.016   −16.49 ± 1.64    368.09   0.412   −16.46
  PLGA15              50                      4                     300   50   221.64 ± 6.78    0.389 ± 0.026   −18.64 ± 1.77    222.34   0.388   −18.61
  PLGA16              300                     4                     300   50   549.67 ± 21.97   0.678 ± 0.040   −32.14 ± 3.09    548.15   0.676   −32.13
  **Axial Points**                                                                                                                                
  PLGA17              75                      2.25                  165   35   348.64 ± 11.19   0.496 ± 0.033   −21.45 ± 2.05    349.06   0.495   −21.44
  PLGA18              425                     2.25                  165   35   414.68 ± 18.67   0.506 ± 0.042   −23.64 ± 2.37    415.64   0.507   −23.61
  PLGA19              175                     1.25                  165   35   313.54 ± 9.91    0.436 ± 0.029   −14.56 ± 2.69    312.47   0.438   −14.50
  PLGA20              175                     5.75                  165   35   496.89 ± 20.54   0.694 ± 0.043   −33.54 ± 4.68    495.05   0.696   −33.55
  PLGA21              175                     2.25                  105   35   233.65 ± 6.92    0.405 ± 0.031   −16.64 ± 1.94    234.24   0.404   −16.65
  PLGA22              175                     2.25                  435   35   311.69 ± 9.68    0.589 ± 0.053   −21.64 ± 2.11    313.74   0.590   −21.62
  PLGA23              175                     2.25                  165   5    468.64 ± 19.16   0.711 ± 0.064   −31.64 ± 3.64    469.56   0.712   −31.61
  PLGA24              175                     2.25                  165   65   331.54 ± 11.09   0.642 ± 0.039   −19.34 ± 1.91    330.05   0.641   −19.32
  **Centre Points**                                                                                                                               
  PLGA25              175                     2.25                  165   35   289.64 ± 12.08   0.569 ± 0.059   --20.56 ± 2.09   291.01   0.570   --21.06
  PLGA26              175                     2.25                  165   35   289.64 ± 12.08   0.569 ± 0.059   --20.56 ± 2.09   291.01   0.570   --21.06
  PLGA27              175                     2.25                  165   35   289.64 ± 12.08   0.569 ± 0.059   --20.56 ± 2.09   291.01   0.570   --21.06
  PLGA28              175                     2.25                  165   35   289.64 ± 12.08   0.569 ± 0.059   --20.56 ± 2.09   291.01   0.570   --21.06
  PLGA29              175                     2.25                  165   35   289.64 ± 12.08   0.569 ± 0.059   --20.56 ± 2.09   291.01   0.570   --21.06
  PLGA30              175                     2.25                  165   35   289.64 ± 12.08   0.569 ± 0.059   --20.56 ± 2.09   291.01   0.570   --21.06
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###### 

Summary of regression analysis for responses Y~1~ (particle size in nm), Y~2~ (PDI), and Y~3~ (Zeta potential).

  Quadratic Model   R^2^     Adjusted R^2^   Predicted R^2^   SD       \% Coefficient of Variation (CV)
  ----------------- -------- --------------- ---------------- -------- ----------------------------------
  Response (Y~1~)   0.9938   0.9879          0.9833           2.52     4.02
  Response (Y~2~)   0.9927   0.9858          0.9805           0.0177   4.13
  Response (Y~3~)   0.9993   0.9986          0.9980           0.2578   1.20
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###### 

Optimal predicted and optimized batch of CH--PLGA--NPs with independent variables and dependent variables with other characterizations of optimized CH--PLGA--NPs.

  ----------------------------------- --------------------------- ------------------------- --------------------------- ------------------ -------------- ----------------------- ---------------
  **Batch**                           **Independent Variables**   **Dependent Variables**                                                                                         
                                      X~1~                        X~2~                      X~3~                        X~4~               Y~1~           Y~2~                    Y~3~
  Predicted                           50.7                        1.20                      100                         28                 94.14          0.108                   −12.61
  Optimized                           50.0                        1.10                      90                          25                 93.46 ± 3.94   0.106 ± 0.01            −12.63 ± 0.08
  **Optimized Dependent Variables**   **Actual/Observed Value**   ***p*-Value**             **Entrapment Efficiency**   **Drug Loading**   **pH**         **Process Yield (%)**   
  Particle Size                       93.46 nm                    \<0.0001                  73.69 ± 3.16                4.73 ± 0.11        7.4 ± 0.18     76.69 ± 3.41%           
  PDI                                 0.106                       \<0.0001                                                                                                        
  Zeta Potential (mV)                 −12.63                      \<0.0001                                                                                                        
  ----------------------------------- --------------------------- ------------------------- --------------------------- ------------------ -------------- ----------------------- ---------------

pharmaceutics-12-00203-t005_Table 5

###### 

Chitosan coating above selected optimized CH-loaded--PLGA--NPs tried 1% and 2% CS concentration.

  Formulation Code                              Chitosan (%)   pH    Mean Particle Size (nm) ± SD   Polydispersity Index (PDI) ± SD   Zeta Potential (mV)   Entrapment Efficiency (EE%) ± SD   Drug Loading (DL%) ± SD
  --------------------------------------------- -------------- ----- ------------------------------ --------------------------------- --------------------- ---------------------------------- -------------------------
  CS-coated-optimized--CH-loaded--PLGA--NPs 1   2              7.4   106.31 ± 2.91                  0.239 ± 0.008                     21.64 ± 1.04          80.36 ± 4.01                       5.98 ± 0.36
  CS-coated-optimized--CH-loaded--PLGA--NPs 2   4              7.4   142.43 ± 3.94                  0.364 ± 0.023                     24.34 ± 1.59          81.66 ± 4.61                       6.87 ± 0.49

CH: catechin hydrate, PLGA: poly(lactic-*co*-glycolic acid), NPs: nanoparticles, CS: chitosan, SD: standard deviation, PDI: polydispersity index, DL: drug loading, EE: entrapment efficiency.
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###### 

Validation: precision and accuracy data for catechin hydrate (CH) in different biomatrixes. LOQQC, lower limit of quantification for quality control; LQC, lower QC; MQC, medium QC; HQC, high QC.

  Biomatrix          Quality Controls Samples   Theoretical Concentration (ng mL^−1^) or (ng g^−1^)   Intra-Batch Precision   Inter-Batch Precision   Recovery (%)                                   
  ------------------ -------------------------- ----------------------------------------------------- ----------------------- ----------------------- ---------------- ------------- ------- ------- -------
  Brain Homogenate   LOQQC                      1.01                                                  0.99 ± 0.03             98.02                   3.03             0.98 ± 0.04   97.03   2.90    81.47
  LQC                2.90                       2.85 ± 0.09                                           98.28                   3.16                    2.84 ± 0.11      97.93         2.44    83.48   
  MQC                410.00                     407.61 ± 11.36                                        99.41                   2.79                    403.17 ± 12.54   98.33         1.42    80.17   
  HQC                800.00                     789.67 ± 18.64                                        98.47                   3.81                    784.69 ± 19.21   98.09         0.72    81.38   
  Lungs Homogenate   LOQQC                      1.01                                                  0.98 ± 0.04             97.03                   4.08             0.97 ± 0.06   96.04   2.34    80.25
  LQC                2.90                       2.83 ± 0.11                                           97.59                   3.89                    2.81 ± 0.16      96.90         1.04    81.67   
  MQC                410.00                     404.71 ± 13.02                                        98.71                   3.22                    402.37 ± 14.17   98.14         0.59    82.49   
  HQC                800.00                     779.25 ± 19.61                                        97.41                   2.52                    775.43 ± 20.18   96.93         0.39    81.52   
  Plasma             LOQQC                      1.01                                                  0.96 ± 0.03             95.05                   3.13             0.94 ± 0.04   93.07   2.32    80.57
  LQC                2.90                       2.86 ± 0.14                                           98.62                   4.90                    2.85 ± 0.15      98.28         1.94    82.61   
  MQC                410.00                     402.33 ± 11.42                                        98.13                   2.84                    401.34 ± 12.69   97.89         0.66    83.46   
  HQC                800.00                     778.67 ± 21.64                                        97.33                   2.78                    774.18 ± 22.37   96.77         0.39    84.51   

Values (mean ± SD) are derived from six replicates.
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###### 

Validation: stability data for catechin hydrate (CH) in different biomatrixes.

  Exposure Condition                                                                   LQC (2.90 ng/mL or ng g^−1^)   MQC (410.00 ng/mL or ng g^−1^)   HQC (800.00 ng/mL or ng g^−1^)                                                                                                                                    
  ------------------------------------------------------------------------------------ ------------------------------ -------------------------------- -------------------------------- ------------------------- ------------------------- ------------------------ ------------------------- ------------------------- -------------------------
  **Long-term stability; recovery (ng) after storage (−80 °C)**                                                                                                                                                                                                                                                          
  Previous day                                                                         2.84 ± 0.11                    2.86 ± 0.10                      2.85 ± 0.10                      406.35 ± 11.36            407.11 ± 10.08            406.93 ± 9.36            794.36 ± 13.38            792.48 ± 12.93            789.45 ± 13.64
  30th Day                                                                             2.81 ± 0.10 (98.94%)           2.83 ± 0.14 (98.95%)             2.82 ± 0.11 (98.95%)             400.24 ± 9.21 (98.50%)    399.25 ± 8.96 (98.07%)    400.21 ± 9.28 (98.35%)   777.43 ± 12.97 (97.87%)   781.64 ± 11.67 (98.63%)   776.78 ± 12.32 (98.40%)
  **Freeze--thaw stress; recovery (ng) after freeze--thaw cycles (−80 °C to 25 °C)**                                                                                                                                                                                                                                     
  Pre-Cycle                                                                            2.87 ± 0.09                    2.89 ± 0.09                      2.88 ± 0.09                      407.14 ± 10.22            406.15 ± 9.34             405.33 ± 9.37            792.47 ± 13.57            790.45 ± 12.31            789.49 ± 11.64
  First Cycle                                                                          2.84 ± 0.11 (98.95%)           2.87 ± 0.08 (99.31%)             2.85 ± 0.07 (98.96%)             403.25 ± 9.24 (99.04%)    402.34 ± 10.04 (99.06%)   401.24 ± 9.01 (98.99%)   784.19 ± 11.38 (98.96%)   781.44 ± 12.10 (98.86%)   777.41 ± 12.48 (98.47%)
  Second Cycle                                                                         2.81 ± 0.10 (97.91%)           2.85 ± 0.09 (98.62%)             2.84 ± 0.08 (98.61%)             400.14 ± 9.04 (98.28)     399.28 ± 9.03 (98.31%)    396.32 ± 8.94 (97.78%)   771.58 ± 12.02 (97.36%)   773.24 ± 11.64 (97.82%)   761.58 ± 14.64 (96.46%)
  Third Cycle                                                                          2.79 ± 0.08 (97.21%)           2.82 ± 0.07 (97.58%)             2.82 ± 0.07 (97.92%)             397.16 ± 10.04 (97.55%)   392.14 ± 11.04 (96.55%)   390.18 ± 9.01 (96.26%)   764.28 ± 12.09 (96.44)    763.24 ± 13.08 (96.56%)   753.49 ± 10.39 (95.44%)
  **Bench top stability; recovery (ng) at room temperature (25 °C)**                                                                                                                                                                                                                                                     
  0 h                                                                                  2.88 ± 0.07                    2.89 ± 0.09                      2.88 ± 0.07                      408.01 ± 11.01            405.97 ± 10.13            406.48 ± 10.17           791.41 ± 11.92            793.46 ± 13.01            791.61 ± 12.07
  24 h                                                                                 2.85 ± 0.08 (96.96%)           2.87 ± 0.07 (99.31%)             2.83 ± 0.04 (98.26%)             399.97 ± 10.16 (98.03%)   399.46 ± 9.63 (98.40%)    399.94 ± 9.64 (99.39%)   779.94 ± 12.06 (98.55%)   778.92 ± 11.64 (98.17%)   780.06 ± 13.08 (98.54%)
  **Post-processing stability; recovery (ng) after storage in auto sampler (4 °C)**                                                                                                                                                                                                                                      
  0 h                                                                                  2.85 ± 0.07                    2.87 ± 0.06                      2.88 ± 0.09                      404.36 ± 8.94             406.14 ± 9.43             407.36 ± 10.00           790.34 ± 11.56            789.64 ± 11.64            791.25 ± 12.32
  4 h                                                                                  2.82 ± 0.06 (98.95%)           2.84 ± 0.07 (98.95%)             2.83 ± 0.06 (98.26%)             398.99 ± 9.02 (98.67%)    399.04 ± 8.81 (98.25%)    401.03 ± 9.34 (98.45%)   779.86 ± 12.34 (98.67%)   774.64 ± 12.08 (98.10%)   776.34 ± 10.05 (98.12%)

Values (mean ± SD) are derived from six replicates. Figures in parenthesis represent analyte concentration (%) relative to time zero. Theoretical contents: LQC: 2.90 ng mL^−1^; MQC: 410.00 ng mL^−1^; and HQC: 800.00 ng mL^−1.^
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###### 

Definitions and formulas used in the calculations.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Accuracy (%) = Mean value of \[(mean observed concentration)/(theoretical concentration)\] × 100;
  Precision (%): Coefficient of variance (percentage) = standard deviation divided by mean concentration found × 100;
  Recovery (%) = Mean value of (peak height (mV) obtained from extracted biological sample)/(peak height (mV) obtained from aqueous sample) × 100.
  --------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Pharmacokinetics (PKs) of catechin hydrate after i.n. and i.v. administration to rats at the dose of 10 mg kg^−1^ in the brain, lungs, and plasma (*n* = 6, mean ± SD). AUC, area under curve.

  --------------------------------------------------------------- ----------------- -------------------- ----------------------- ------------------- ------------------- -----------------------------
  **Formulation Administration**                                  **Samples**       **Cmax (ng/mL g)**   **T~max~**              **t~1/2~ (h)**      **Ke (h^−1^)**      **AUC~0--t~ (ng min/mL g)**
  CH--S (i.n.)                                                    Brain             81.68 ± 10.13        2.00                    15.25 ± 2.06        0.04544 ± 0.0006    977.32 ± 33.14
  Lungs                                                           28.64 ± 3.09      2.00                 21.77 ± 2.19            0.03184 ± 0.00011   373.85 ± 16.47      
  Plasma                                                          32.02 ± 2.63      0.50                 8.23 ± 3.10             0.08420 ± 0.0009    170.48 ± 18.43      
  CH--S (i.v.)                                                    Brain             44.23 ± 7.04         2.00                    11.16 ± 0.39        0.06210 ± 0.0009    395.26 ± 19.47
  Lungs                                                           95.43 ± 18.14     2.00                 9.19 ± 0.81             0.07540 ± 0.00051   958.79 ± 34.64      
  Plasma                                                          1141.54 ± 83.45   0.50                 4.69 ± 0.29             0.14767 ± 0.0018    3167.33 ± 55.67     
  CH--PLGA--NPs (i.n.)                                            Brain             623.36 ± 24.21       2.00                    24.71 ± 4.59        0.02806 ± 0.00006   7785.90 ± 83.64
  Lungs                                                           106.97 ± 11.97    2.00                 11.00 ± 1.01            0.06303 ± 0.00011   1033.42 ± 44.67     
  Plasma                                                          56.78 ± 4.64      2.00                 8.26 ± 0.97             0.08391 ± 0.00008   409.41 ± 25.94      
  CS--CH--PLGA--NPs (i.n.)                                        Brain             996.24 ± 44.24       2.00                    21.81 ± 3.94        0.03178 ± 0.00008   12444.50 ± 139.25
  Lungs                                                           121.64 ± 18.45    2.00                 11.21 ± 2.88            0.06184 ± 0.0008    1187.01 ± 31.04     
  Plasma                                                          99.67 ± 10.18     2.00                 9.33 ± 0.94             0.07427 ± 0.00013   936.04 ± 86.79      
  CH--PLGA--NPs (i.v.)                                            Brain             98.36 ± 19.55        2.00                    15.91 ± 3.06        0.04355 ± 0.00010   1170.58 ± 28.57
  Lungs                                                           109.94 ± 7.98     2.00                 11.52 ± 2.97            0.06016 ± 0.0005    1091.68 ± 34.67     
  Plasma                                                          757.54 ± 33.16    1.00                 16.65 ± 1.06            0.04162 ± 0.0007    9430.18 ± 189.67    
  CS--CH--PLGA--NPs (i.v.)                                        Brain             126.48 ± 17.61       2.00                    67.83 ± 5.47        0.01022 ± 0.00006   1959.57 ± 79.68
  Lungs                                                           136.48 ± 15.97    2.00                 62.03 ± 2.91            0.01117 ± 0.0010    1974.57 ± 44.89     
  Plasma                                                          1064.43 ± 96.43   1.00                 15.83 ± 1.06            0.04378 ± 0.0006    12948.59 ± 277.13   
  CH--S (i.n.)                                                    Brain/Plasma      2.55                 4.00                    1.85                0.54                5.73
  CH--S (i.v.)                                                    Brain/Plasma      0.039                4.00                    2.38                0.42                0.13
  CH--PLGA--NPs (i.n.)                                            Brain/Plasma      10.98                1.00                    2.99                0.34                19.02
  CH--PLGA--NPs (i.v.)                                            Brain/Plasma      0.13                 2.00                    0.96                1.05                0.12
  CS--CH--PLGA--NPs (i.n.)                                        Brain/Plasma      10.00                1.00                    2.34                0.43                13.29
  CS--CH--PLGA--NPs (i.v.)                                        Brain/Plasma      0.13                 2.00                    4.29                0.23                0.15
  **Comparative Bioavailability \* (AUC~i.n.~/AUC~i.v.~); (%)**                                                                                                          
  **Formulations**                                                **CH--S**         **CH--PLGA--NPs**    **CS--CH--PLGA--NPs**                                           
  Blood                                                           5.38              4.34                 7.23                                                            
  Brain                                                           247.26 \*         665.13 \*\*          1063.11 \*\*\*                                                  
  --------------------------------------------------------------- ----------------- -------------------- ----------------------- ------------------- ------------------- -----------------------------

\* Parameters are derived using mean ± SEM values of six different estimations. For the *p*-value: \*\*\* (*p* \< 0.001), \*\* (*p* \< 0.01), and \* (*p* \< 0.05).
